We are live on ! Find out more
KCA

KVP Capital Advisors Portfolio holdings

AUM $136M Turnover 23.68%
This Fund
S&P 500
This Quarter Est. Return
+167.4%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$103M
AUM Growth
–
Cap. Flow
+$78.5M
Cap. Flow %
76.01%
Top 10 Hldgs %
68.49%
Holding
27
New
27
Increased
–
Reduced
–
Closed
–
Avg Time Held Equity + Options
0 years
Top 10 Avg Time Held Equity + Options
0 years
Top 20 Avg Time Held Equity + Options
0 years
Avg Time Held Equity only
0 years
Top 10 Avg Time Held Equity only
0 years
Top 20 Avg Time Held Equity only
0 years

Top Buys

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$10.2M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$7.99M
3
INSM icon
Insmed
INSM
+$5.2M
4
AXSM icon
Axsome Therapeutics
AXSM
+$5.05M
5
WHWK icon
Whitehawk Therapeutics
WHWK
+$4.97M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 93.69%
2 Miscellaneous 6.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TERN icon
1
DELISTED
Terns Pharmaceuticals
TERN
$17.8M 17.2%
+440,000
New +$10.2M
2025 Q4
0 quarters
PRAX icon
2
Praxis Precision Medicines
PRAX
$6.93B
$12.6M 12.24%
+42,900
New +$7.99M
2025 Q4
0 quarters
AXSM icon
3
Axsome Therapeutics
AXSM
$8.47B
$6.61M 6.4%
+36,200
New +$5.05M
2025 Q4
0 quarters
JAZZ icon
4
CALL
Jazz Pharmaceuticals
JAZZ
$13.9B
$5.27M 5.1%
+31,000
New +$4.75M
2025 Q4
0 quarters
WHWK icon
5
Whitehawk Therapeutics
WHWK
$173M
$5.24M 5.07%
+2,165,997
New +$4.97M
2025 Q4
0 quarters
TRVI icon
6
Trevi Therapeutics
TRVI
$1.73B
$5.18M 5.02%
+414,000
New +$4.78M
2025 Q4
0 quarters
INSM icon
7
Insmed
INSM
$21.7B
$4.96M 4.8%
+28,497
New +$5.2M
2025 Q4
0 quarters
PTGX icon
8
Protagonist Therapeutics
PTGX
$8.84B
$4.63M 4.48%
+53,000
New +$4.34M
2025 Q4
0 quarters
IRON icon
9
Disc Medicine
IRON
$2.17B
$4.63M 4.48%
+58,250
New +$4.92M
2025 Q4
0 quarters
MBX icon
10
MBX Biosciences
MBX
$2.44B
$3.83M 3.71%
+121,524
New +$2.95M
2025 Q4
0 quarters
SVRA icon
11
Savara
SVRA
$974M
$3.65M 3.53%
+605,280
New +$2.96M
2025 Q4
0 quarters
TVTX icon
12
Travere Therapeutics
TVTX
$4.98B
$3.48M 3.36%
+91,000
New +$2.96M
2025 Q4
0 quarters
EWTX icon
13
Edgewise Therapeutics
EWTX
$4.15B
$3.3M 3.19%
+133,000
New +$2.67M
2025 Q4
0 quarters
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$13.9B
$2.98M 2.88%
+17,500
New +$2.68M
2025 Q4
0 quarters
SLNO icon
15
DELISTED
Soleno Therapeutics
SLNO
$2.76M 2.67%
+59,700
New +$3.27M
2025 Q4
0 quarters
UTHR icon
16
United Therapeutics
UTHR
$23.2B
$2.31M 2.24%
+4,750
New +$2.21M
2025 Q4
0 quarters
ACHV icon
17
Achieve Life Sciences
ACHV
$719M
$2.3M 2.22%
+462,355
New +$2.02M
2025 Q4
0 quarters
RVMD icon
18
Revolution Medicines
RVMD
$40.6B
$2.19M 2.12%
+27,500
New +$1.8M
2025 Q4
0 quarters
SRRK icon
19
Scholar Rock
SRRK
$4.95B
$1.98M 1.92%
+45,000
New +$1.69M
2025 Q4
0 quarters
VERA icon
20
Vera Therapeutics
VERA
$2.06B
$1.66M 1.6%
+32,700
New +$1.16M
2025 Q4
0 quarters
FULC icon
21
CALL
Fulcrum Therapeutics
FULC
$280M
$1.25M 1.21%
+110,900
New +$1.13M
2025 Q4
0 quarters
IMMX icon
22
Immix Biopharma
IMMX
$720M
$1.21M 1.17%
+230,423
New +$948K
2025 Q4
0 quarters
NKTR icon
23
Nektar Therapeutics
NKTR
$1.29B
$1.14M 1.1%
+26,900
New +$1.51M
2025 Q4
0 quarters
CABA icon
24
Cabaletta Bio
CABA
$263M
$1.11M 1.07%
+505,431
New +$1.25M
2025 Q4
0 quarters
FULC icon
25
Fulcrum Therapeutics
FULC
$280M
$566K 0.55%
+50,000
New +$509K
2025 Q4
0 quarters
1
2

Similar funds

RC
Rahlfs Capital Lake Kiowa, Texas $136M AUM 33.89% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $136M AUM 23.45% 1-Year Est. Return
SB
Semitam Bonam Goshen, New York $136M AUM 13.42% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
FEM
Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return
SCM
Sidoxia Capital Management Newport Beach, California $136M AUM
VSCP
Vesey Street Capital Partners New York $136M AUM 6.83% 1-Year Est. Return

KVP Capital Advisors's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for KVP Capital Advisors, which disclosed 27 positions worth $103M. Its ten largest holdings account for 68% of the portfolio.

Its largest position is Terns Pharmaceuticals: 440,000 shares worth $17.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, followed by Miscellaneous.

  • KVP Capital Advisors's largest Q4 2025 buy was Terns Pharmaceuticals: 440,000 shares worth $17.8M.
  • KVP Capital Advisors's ten largest holdings make up 68% of its $103M portfolio in Q4 2025.
  • KVP Capital Advisors disclosed 27 positions in Q4 2025, its first 13F filing on record.

Based on KVP Capital Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.